Bioequivalency Study of Fenofibrate 160mg Tablets Under Fasting Conditions

Ranbaxy

Status

Completed

Conditions

Healthy

Treatments

Drug: fenofibrate 160 mg tablets

Study type

Interventional

Funder types

Industry

Identifiers

NCT00775827

028/FENOF-160/02

Details and patient eligibility

About

The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose crossover bioavailability study on fenofibrate formulations comparing fenofibrate 160 mg tablets of Ranbaxy Laboratories with Tricor 160 mg tablets in healthy, adult, human subjects under fasting conditions.

Full description

This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 40 healthy adult male subjects.

As per protocol, enough healthy, adult, human subjects were to be enrolled in the study to allow the dosing of 40 subjects in the first period. 40 subjects were enrolled and a total of 37 subjects completed both the periods of study.

Enrollment

40 patients

Sex

Male

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Be in the age range of 18-45 years.
Be neither overweight nor underweight for his/her height as per te Life insurance Corporation of india height/weight chart for non-medical cases.
Have voluntarily given written informed consent to participate in this study.

Be of normal health as determined by medical history and physical examination of the subjects performed within 28 days prior to the commencement of the study.

If female and:

Of childbearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence; or TS postmenopausal for at least 1 year; or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

Exclusion criteria

History of allergy to fenofibrate and related fibric acid derivatives.

History of gall stones/cholecystitis
Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.
Presence of disease markers of H~-I and 2, Hepatitis B and C viruses and syphilis infection.

Female volunteers demonstrating a positive pregnancy screen.

Female volunteers who are currently breasffeeding.

Presence of values which are clinically significantly different from normal reference ranges (as defined in Appendix 5) for haemoglobin, total white blood cells count, differential WBC count and platelet count.
Positive for urinary screen testing of drugs of abuse (opiates and cannabinoids)
Presence of values which are significantly different from normal reference ranges (as defined in Appendix 5) for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose, serum cholesterol and serum triglycerides.

Clinically abnormal chemical and microscopic examination of urine defined as presence .of RBC, WBC (>4/HPF), epithelial cells (>4/HPF), glucose (positive) and protein (positive).

Clinically abnormal ECG and Chest X-ray.

History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes or glaucoma.
History of any psychiatric illness which may impair the ability to provide written informed consent.
Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period.
History of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (! Unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the'duration of each study period.

Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study.

Participation in any clinical trial within 6 weeks preceding Day ! of this study.